According to our new research study on "High Intensity Focused Ultrasound Therapy Market Forecast to 2031 - Global Analysis - by Modality, Application, End User, and Geography," the market is expected to grow from US$ 505.49 million in 2024 to US$ 879.87 million by 2031; it is estimated to record a CAGR of 8.3% from 2025-2031. Key factors driving the growth of the high intensity focused ultrasound therapy market are the rising prevalence of chronic diseases and cancer, and soaring preference for noninvasive procedures.

The scope of the high intensity focused ultrasound therapy market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. Asia Pacific is anticipated to register the fastest CAGR in the high intensity focused ultrasound therapy market from 2025 to 2031. The increasing number of cancer cases and other chronic diseases, mainly in densely populated countries like China, India, and Japan, is the main factor that makes patients prefer non-invasive treatment methods such as the HIFU. Both patients and medical staff have been made aware of the benefits of HIFU, which is why its use is spreading quickly. HIFU has fewer side effects, less hospitalization, and a quicker recovery. Governments efforts to enhance the healthcare sector are the main reasons for the demand for advanced medical technologies. Also, the growing urbanization, the increase in disposable incomes, and the rise of private healthcare providers are some of the factors that are causing the demand for innovative treatments to go up, thereby bolstering the high intensity focused ultrasound therapy market growth in the Asia Pacific. By collaborating with regional and international medical device companies and implementing various technological advancements, the costs of HIFU systems have been dropping and more people have access to them, accelerating the growth of the Asia-Pacific high intensity focused ultrasound therapy market in the near future. The focus on clinical research and clinical trials in countries such as South Korea and China is raising at a fast pace; thus, it is a significant driver of innovation and fast regulatory approvals. Moreover, the elderly population in the region that is more prone to diseases that can be treated by HIFU is becoming a significant factor aiding the high intensity focused ultrasound therapy market in the region.

China reported over 659,000 cancer cases related to hormones (including breast and prostate) that exploded in 6 kinds of cancers in 2021, of which more than half of the cases were female. As a pioneer since 1999, Chongqing Haifu Medical Technology Co., Ltd. has local systems developed, such as the JC focused ultrasound tumor therapy device, which allows clinical integration at big centers, for instance, Fuda Cancer Hospital and Shanghai Cancer Center. A multinational agreement between Chinese and European centers in June 2024, detailed the ultrasound-guided HIFU protocols for pancreatic cancer, highlighting that the energy-based dosing should be for inoperable cases and the combination with chemotherapy to prolong the survival, further fueling the growth of high intensity focused ultrasound therapy market. A groundbreaking event at the Second Affiliated Hospital of Chongqing Medical University in July 2024, witnessed the use of HIFU to successfully treat the recurrence of mucinous ovarian cancer, leading to the decrease of CA-199 markers after therapy, with the help of a rectal Foley catheter for safe posterior field protection. All these innovations, along with NMPAs relaxed IND approvals in July 2024, represent a move toward multimodal uses, such as neuromodulation for essential tremor.

Furthermore, the high intensity focused ultrasound therapy market is accelerating with several developments in the region. In 2024, SONIRE Therapeutics, a company from Tokyo, created a next-generation HIFU system for unresectable pancreatic cancer, and the US FDA has recognized it as a Breakthrough Device. The device is receiving local backing through the Deep-Tech Startup Support Program by NEDO (Japans New Energy and Industrial Technology Development Organization) which is designed to speed up product development, supporting the high intensity focused ultrasound therapy market growth. Therefore, the factors mentioned above are promoting a favorable environment for the high intensity focused ultrasound therapy market in the region.

EDAP TMS SA, Sonablate Corp, Koninklijke Philips NV, CLASSYS Inc., Insightec, Hironic Co. Ltd, FUS Instruments Inc., Chongqing Haifu Medical Technology Co. Ltd, Theraclion, Image Guided Therapy, Verasonics Inc., Lynton Lasers Ltd, WON TECH Co. Ltd., and Jeisys Global are among the leading companies profiled in the high intensity focused ultrasound therapy market report.

Based on modality, the high intensity focused ultrasound therapy market is bifurcated into MRI guided focused ultrasound therapy and ultrasound guided therapy. By application, the market is segmented into breast cancer, prostate cancer, liver cancer, pancreatic cancer, breast lifting and aesthetic application, nipple and areola preservation, post surgical applications, and others. On the basis of end user, the high intensity focused ultrasound therapy market is classified into healthcare facilities, diagnostic imaging centers and research centers. Geographically, the high intensity focused ultrasound therapy market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com